Skip to main content
. Author manuscript; available in PMC: 2017 Sep 10.
Published in final edited form as: J Control Release. 2017 Jun 27;261:105–112. doi: 10.1016/j.jconrel.2017.06.022

Figure 7. Vismodegib improves anti-tumor efficacy of nanotherapeutics.

Figure 7

Tumor volume growth rates of orthotopic MCF10CA1a breast tumors implanted in CD1 nude mice that were either mock-treated (0.9% NaCl for Abraxane, saline for Doxil and MCT-0.5% methylcellulose, 0.2% Tween 80- for vismodegib), vismodegib-treated alone (40 mg/kg daily via gavage), Doxil alone (3 mg/kg on days 14 and 21 post-implantation, i.v.), Abraxane alone (20 mg/kg on days 14 and 21 post-implantation, i.v.), or vismodegib in combination with either Doxil or Abraxane, as described above. Abraxane alone had no effect on tumor volume, compared to combined administration of vismodegib and Abraxane, which significantly delayed tumor growth (p = 0.02 on day 28, n = 6-8). Additionally, whereas Doxil (3mg/kg) monotherapy had no effect, combination of vismodegib and Doxil significantly decreased tumor volume (p = 2E-6 on day 28, n = 6-8) compared to Doxil alone. Asterisks indicate a statistically significant difference between compared groups (p < 0.05).